Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Escient Pharmaceuticals

News headline image
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Atopic Dermatitis
From Escient Pharmaceuticals
Via Business Wire
News headline image
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
From Escient Pharmaceuticals
Via Business Wire
News headline image
Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in Inhibition of Mast Cell Degranulation in Multiple Species at the European Academy of Allergy and Clinical Immunology
From Escient Pharmaceuticals
Via Business Wire
News headline image
Escient Pharmaceuticals Announces Presentation of Data Demonstrating Efficacy of EP262 in a Mouse Model of Atopic Dermatitis at the American Academy of Dermatology Annual Meeting
From Escient Pharmaceuticals
Via Business Wire
News headline image
Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Pharmacology of EP262 at the American Academy of Allergy, Asthma and Immunology Annual Meeting
From Escient Pharmaceuticals
Via Business Wire
News headline image
Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders
From Escient Pharmaceuticals
Via Business Wire
News headline image
Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th GA2LEN Global Urticaria Forum
From Escient Pharmaceuticals
Via Business Wire
News headline image
Escient Pharmaceuticals Announces $120 Million Series C Financing
From Escient Pharmaceuticals
Via Business Wire
News headline image
Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547, An Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus
From Escient Pharmaceuticals
Via Business Wire
News headline image
Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires
From Escient Pharmaceuticals
Via Business Wire
News headline image
Escient Pharmaceuticals Appoints Joshua Grass, MBA as CEO
From Escient Pharmaceuticals
Via Business Wire
News headline image
Escient Pharmaceuticals Announces Data Presentations Highlighting the Preclinical and Clinical Development of EP547 at AASLD The Liver Meeting® Digital Experience 2021
From Escient Pharmaceuticals
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.